Offerings (SEC Form D)
Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.
Offerings at a glance — 7 offerings, 9 filings (one row per SEC file number)
| File no. | Original Form D | Latest filing | Amendments | Offered (latest) | Sold (latest) | Industry (latest) |
|---|
| 021-552768 | Jul 25, 2025 EDGAR ↗ | Jul 25, 2025 D EDGAR ↗ | 0 | $38,286,410 | $28,548,588 | Biotechnology |
| 021-456056 | Aug 16, 2022 EDGAR ↗ | Jul 24, 2024 D/A EDGAR ↗ | 1 latest Jul 24, 2024 | $22,800,000 | $22,486,953 | Biotechnology |
| 021-419490 | Nov 2, 2021 EDGAR ↗ | Nov 2, 2021 D EDGAR ↗ | 0 | $5,761,644 | $3,490,000 | Biotechnology |
| 021-376488 | Sep 28, 2020 EDGAR ↗ | Sep 28, 2020 D EDGAR ↗ | 0 | $5,000,000 | $3,021,475 | Biotechnology |
| 021-315891 | Jul 2, 2018 EDGAR ↗ | Jul 2, 2018 D EDGAR ↗ | 0 | $2,500,000 | $1,561,500 | Biotechnology |
| 021-270938 | Sep 20, 2016 EDGAR ↗ | Nov 10, 2016 D/A EDGAR ↗ | 1 latest Nov 10, 2016 | $3,100,000 | $1,072,281 | Biotechnology |
| 021-261298 | Apr 14, 2016 EDGAR ↗ | Apr 14, 2016 D EDGAR ↗ | 0 | $200 | $11 | Biotechnology |
Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.
Jul 25, 2025 D Biotechnology — $28,548,588 sold of $38,286,410 · 174 investors EDGAR ↗
| Filing | Form D filed Jul 25, 2025SEC file no. 021-552768 · accession 0000929638-25-002712 |
|---|
| Raise progress | $28,548,588 sold of $38,286,410 offered (75%) · $9,737,822 remaining · first sale Apr 16, 2025 |
|---|
| Filing timing | Date of first sale: Apr 16, 2025 · Form D filed: Jul 25, 2025 (100 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 556 days (1.5 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 174 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity; Other: Convertible Promissory Notes; Series B Preferred Stock underlying the convertible promissory notes |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $52,183 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Jim Buck, President and CEO for the Issuer (Jul 24, 2025) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $38,286,410. Typical range: $2,000,000–$19,999,994.
Investors: 174. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Jul 24, 2024 D/A Biotechnology — $22,486,953 sold of $22,800,000 · 151 investors EDGAR ↗
| Filing | Form D/A (amendment) filed Jul 24, 2024 · amends 0001567619-22-016358 ↗SEC file no. 021-456056 · accession 0000929638-24-002569 · filing 2 of 2 in this offering |
|---|
| Raise progress | $22,486,953 sold of $22,800,000 offered (99%) · $313,047 remaining · first sale Jul 29, 2022 |
|---|
| Filing timing | Date of first sale: Jul 29, 2022 · Original Form D filed: Aug 16, 2022 (18 days after first sale) · This amendment (Form D/A) filed: Jul 24, 2024 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 1,548 days (4.2 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Jul 24, 2024. Most recent amendment for this offering in our index: this filing, Jul 24, 2024. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 151 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity; Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise; Other: Convertible Promissory Notes; Common Stock or Series A-1 Preferred Stock underlying the convertible promissory notes. |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | None — no CRD number reported · associated broker-dealer: Donald Capital LLC (CRD 297763 ↗) Solicits in: AZ, CA, CO, CT, FL, GA, IL, NC, NJ, NM, NV, NY, OK, PA, SC, TN, TX, UT, WI, WY |
|---|
| Money to insiders | Sales commissions: $118,956 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Jim Buck, President and CEO for the Issuer (Jul 21, 2024) |
|---|
| Changes vs previous filing | - total sold: $3,207,050 (Aug 16, 2022) → $22,486,953 (Jul 24, 2024)
- total offering: $5,600,000 (Aug 16, 2022) → $22,800,000 (Jul 24, 2024)
- remaining: $2,392,950 (Aug 16, 2022) → $313,047 (Jul 24, 2024)
- investors: 26 (Aug 16, 2022) → 151 (Jul 24, 2024)
- sales commissions: $0 (Aug 16, 2022) → $118,956 (Jul 24, 2024)
- related persons added (Jul 24, 2024): Abbas Ardehali, M.D., Matthew Dowling, Ph.D
- related persons no longer listed (Jul 24, 2024): Matthew Dowling
- sales-compensation recipients added (Jul 24, 2024): None
Compared with the D filed Aug 16, 2022 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $22,800,000. Typical range: $2,000,000–$19,999,994.
Investors: 151. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Aug 16, 2022 D Biotechnology — $3,207,050 sold of $5,600,000 · 26 investors EDGAR ↗
| Filing | Form D filed Aug 16, 2022SEC file no. 021-456056 · accession 0001567619-22-016358 · filing 1 of 2 in this offering |
|---|
| Raise progress | $3,207,050 sold of $5,600,000 offered (57%) · $2,392,950 remaining · first sale Jul 29, 2022 Issuer's note: The total offering amount includes the interest of 6% on the promissory notes, which interest is convertible into equity securities of the Issuer. |
|---|
| Filing timing | Date of first sale: Jul 29, 2022 · Form D filed: Aug 16, 2022 (18 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 1,548 days (4.2 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Jul 24, 2024 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 26 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity; Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise; Other: Convertible Promissory Notes; Common Stock or Series A-1 Preferred Stock underlying the convertible promissory notes. |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Jim Buck, Chief Executive Officer of the Issuer (Aug 15, 2022) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $5,600,000. Typical range: $2,000,000–$19,999,994.
Investors: 26. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Nov 2, 2021 D Biotechnology — $3,490,000 sold of $5,761,644 · 45 investors EDGAR ↗
| Filing | Form D filed Nov 2, 2021SEC file no. 021-419490 · accession 0001567619-21-019159 |
|---|
| Raise progress | $3,490,000 sold of $5,761,644 offered (61%) · $2,271,644 remaining · first sale Oct 15, 2021 |
|---|
| Filing timing | Date of first sale: Oct 15, 2021 · Form D filed: Nov 2, 2021 (18 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 1,835 days (5.0 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 45 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity; Debt; Option, warrant or other right to acquire; Security to be acquired upon exercise; Other: Convertible Promissory Notes, including Common Stock or Preferred Stock into which the notes can be converted. |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Larry Tiffany, Chief Executive Officer (Nov 1, 2021) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $5,761,644. Typical range: $2,000,000–$19,999,994.
Investors: 45. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Sep 28, 2020 D Biotechnology — $3,021,475 sold of $5,000,000 · 55 investors EDGAR ↗
| Filing | Form D filed Sep 28, 2020SEC file no. 021-376488 · accession 0001567619-20-017138 |
|---|
| Raise progress | $3,021,475 sold of $5,000,000 offered (60%) · $1,978,525 remaining · first sale Jun 19, 2020 |
|---|
| Filing timing | Date of first sale: Jun 19, 2020 · Form D filed: Sep 28, 2020 (101 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 2,318 days (6.4 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 55 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Larry Tiffany, Chief Executive Officer (Sep 21, 2020) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $5,000,000. Typical range: $2,000,000–$19,999,994.
Investors: 55. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Jul 2, 2018 D Biotechnology — $1,561,500 sold of $2,500,000 · 36 investors EDGAR ↗
| Filing | Form D filed Jul 2, 2018SEC file no. 021-315891 · accession 0001672180-18-000001 |
|---|
| Raise progress | $1,561,500 sold of $2,500,000 offered (62%) · $938,500 remaining · first sale Jun 18, 2018 |
|---|
| Filing timing | Date of first sale: Jun 18, 2018 · Form D filed: Jul 2, 2018 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 3,050 days (8.4 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 36 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Debt; Option, warrant or other right to acquire |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Larry Tiffany, President (Jul 2, 2018) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $2,500,000. Typical range: $2,000,000–$19,999,994.
Investors: 36. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Nov 10, 2016 D/A Biotechnology — $1,072,281 sold of $3,100,000 · 14 investors EDGAR ↗
| Filing | Form D/A (amendment) filed Nov 10, 2016 · amends 0001672180-16-000003 ↗SEC file no. 021-270938 · accession 0001672180-16-000004 · filing 2 of 2 in this offering |
|---|
| Raise progress | $1,072,281 sold of $3,100,000 offered (35%) · $2,027,719 remaining · first sale Sep 9, 2016 |
|---|
| Filing timing | Date of first sale: Sep 9, 2016 · Original Form D filed: Sep 20, 2016 (11 days after first sale) · This amendment (Form D/A) filed: Nov 10, 2016 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 3,697 days (10.1 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Nov 10, 2016. Most recent amendment for this offering in our index: this filing, Nov 10, 2016. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 14 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity; Option, warrant or other right to acquire |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Matthew Dowling, President (Nov 10, 2016) |
|---|
| Changes vs previous filing | - total sold: $93,153 (Sep 20, 2016) → $1,072,281 (Nov 10, 2016)
- remaining: $3,006,847 (Sep 20, 2016) → $2,027,719 (Nov 10, 2016)
- investors: 2 (Sep 20, 2016) → 14 (Nov 10, 2016)
- securities offered: Equity (Sep 20, 2016) → Equity; Option, warrant or other right to acquire (Nov 10, 2016)
Compared with the D filed Sep 20, 2016 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $3,100,000. Typical range: $2,000,000–$19,999,994.
Investors: 14. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Sep 20, 2016 D Biotechnology — $93,153 sold of $3,100,000 · 2 investors EDGAR ↗
| Filing | Form D filed Sep 20, 2016SEC file no. 021-270938 · accession 0001672180-16-000003 · filing 1 of 2 in this offering |
|---|
| Raise progress | $93,153 sold of $3,100,000 offered (3%) · $3,006,847 remaining · first sale Sep 9, 2016 |
|---|
| Filing timing | Date of first sale: Sep 9, 2016 · Form D filed: Sep 20, 2016 (11 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 3,697 days (10.1 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Nov 10, 2016 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 2 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Matthew Dowling, President (Sep 20, 2016) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $3,100,000. Typical range: $2,000,000–$19,999,994.
Investors: 2. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Apr 14, 2016 D Biotechnology — $11 sold of $200 · 1 investors EDGAR ↗
| Filing | Form D filed Apr 14, 2016SEC file no. 021-261298 · accession 0001671724-16-000001 |
|---|
| Raise progress | $11 sold of $200 offered (6%) · $189 remaining · first sale Mar 29, 2016 |
|---|
| Filing timing | Date of first sale: Mar 29, 2016 · Form D filed: Apr 14, 2016 (16 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 3,861 days (10.6 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 1 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
|---|
| Minimum investment accepted | $0 as filed (no minimum reported) |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Matthew Dowling, President (Apr 13, 2016) |
|---|
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000.
Offering size: $200. Typical range: $2,000,000–$19,999,994.
Investors: 1. Typical range: 2–16."Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Amendment history — 2 amendments on this page, each compared with the filing before it in the same offering
| Amendment filed | File no. | Compared with | What changed (both values as filed) |
|---|
| Jul 24, 2024 EDGAR ↗ | 021-456056 | Aug 16, 2022 D | total sold: $3,207,050 (Aug 16, 2022) → $22,486,953 (Jul 24, 2024) · total offering: $5,600,000 (Aug 16, 2022) → $22,800,000 (Jul 24, 2024) · remaining: $2,392,950 (Aug 16, 2022) → $313,047 (Jul 24, 2024) · and 5 more (open the filing above) |
| Nov 10, 2016 EDGAR ↗ | 021-270938 | Sep 20, 2016 D | total sold: $93,153 (Sep 20, 2016) → $1,072,281 (Nov 10, 2016) · remaining: $3,006,847 (Sep 20, 2016) → $2,027,719 (Nov 10, 2016) · investors: 2 (Sep 20, 2016) → 14 (Nov 10, 2016) · and 1 more (open the filing above) |
Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Values as filed; no conclusion is drawn.
All Form D filings for this CIK on SEC EDGAR ↗. History: 0 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Jul 25, 2025. Industry as reported, by offering: All 7 offerings reported: Biotechnology (2016–2025).
Key people 8
Officers, directors and promoters the issuer itself named on its Form D. Tap a name for every other deal they are on.
| Name | Relationship | Address state | On filings (first → last) | Also listed on |
|---|
| AD Abbas Ardehali, M.D. | Director | MD | Jul 24, 2024 → Jul 25, 2025 on 2 of 9 filings listed on the latest filing | — |
| JB Jim Buck | Director, Executive Officer Issuer's note: Mr. Buck is the Chief Executive Officer of the Issuer. | MD | Jul 2, 2018 → Jul 25, 2025 on 6 of 9 filings listed on the latest filing | — |
| LT Larry Tiffany | Director, Executive Officer Issuer's note: Chief Executive Officer | MD | Apr 14, 2016 → Jul 25, 2025 on 9 of 9 filings listed on the latest filing | — |
| MD Matthew Dowling, Ph.D | Director, Executive Officer Issuer's note: Dr. Dowling is the Chief Scientic Officer of the Issuer. | MD | Jul 24, 2024 → Jul 25, 2025 on 2 of 9 filings listed on the latest filing | — |
| RV Rich Vincent | Executive Officer Issuer's note: Mr. Vincent is the Chief Financial Officer of the Issuer. | MD | Sep 28, 2020 → Jul 25, 2025 on 5 of 9 filings listed on the latest filing | — |
| MD Matthew Dowling | Executive Officer, Director Issuer's note: Mr. Dowling is the Chief Scientific Officer. | MD | Apr 14, 2016 → Aug 16, 2022 on 7 of 9 filings not listed on the latest filing (Jul 25, 2025) | 1 other issuer |
| AA Alex Arrow | Director | MD | Sep 20, 2016 → Sep 28, 2020 on 4 of 9 filings not listed on the latest filing (Jul 25, 2025) | — |
| PT Peter Thomas | Executive Officer, Director | CA | Apr 14, 2016 on 1 of 9 filings not listed on the latest filing (Jul 25, 2025) | 3 other issuers |
Executive officers, directors and promoters as self-reported by the issuer, one row per person. Spellings of the same name (same first and last name, or the same full name that EDGAR split differently into middle and last name) with no conflicting middle initial are shown on one row (none on this issuer); dates and counts come from the filings that list each name. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
Connections
Other issuers listing the same people:
Shared address: this business address appears on filings for 1 other issuer. Stated as a count only (suite numbers ignored) — many addresses are shared office buildings or registered agents. As of Oct 23, 2026, 5:45 PM ET.
Other offering types (Regulation A and Regulation Crowdfunding)
Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.
Adviser registration (Form ADV)
Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched Medcura, Inc..
Meta advertising
No Meta Pixel ids or Facebook / Instagram page links on file for Medcura, Inc. as of Oct 24, 2026 — the sponsor website is read for them once it is on file (runs automatically). Meta Ad Library: not searched by PartnerFacts (no API access); a one-tap Ad Library search is under Look further.
Public profiles
Public profiles official links and public statements, each with its source and date
No website or social profile named in Medcura, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #65,164 of 374,652 in line (564 issuers searched so far).
Sources searched for a website: Form C data set (issuer websites as filed), Form ADV data set (Item 1.I of matched advisers) — as of Oct 23, 2026, 11:20 PM ET: none on file for this issuer. The sponsor website, the Internet Archive and GDELT news index are read only once a site is on file; a sponsor's website comes from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim, Form ADV Item 1.I of its matched adviser, or a web search for the issuer name confirmed on the site's own homepage. We never collect personal or family accounts.
Entity standing: not checked (no official programmatic source for MD yet).
Export this report as PDF (all source links + data timestamp) · Premium
Request diligence pack (Premium) PartnerFacts asks the sponsor for the standard information pack and delivers it to you labelled "provided by the sponsor".
Corrections log
No corrections have been requested for this page.
Filing-to-filing changes are in Amendment history above.